Intellia's Ntla-2002 Shows Promising Results, but Stock Drops Following Phase 2 Data Release
Based on these findings, Intellia chose the 50 mg dose for their Phase 3 research, HAELO, which is now under enrollment ...
HealthDay on MSN3h
ACAAI: Gene-Editing Therapy Reduces Angioedema Attacks in Hereditary Angioedema
For adults with hereditary angioedema, the in vivo gene-editing therapy NTLA-2002, which is based on clustered regularly ...
Intellia Therapeutics stock plunges after phase 2 results from NTLA-2002 study
Inc. took a nosedive today, dropping around 20% after the company announced results from the Phase 2 study of its ...
Intellia Therapeutics presents results from Phase 2 study of NTLA-2002
Intellia Therapeutics (NTLA) announced positive Phase 2 data from the ongoing Phase 1/2 study of NTLA-2002 in patients with hereditary ...
Why Intellia Therapeutics Stock Plummeted by 20% Today
Thursday was hardly a good day to be a shareholder of Intellia Therapeutics (NASDAQ: NTLA). After the biotech delivered some ...
FierceBiotech13h
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks in phase 2
Intellia Therapeutics has taken another step toward its goal of winning the first approval for an in vivo CRISPR therapy, ...
Intellia Therapeutics price target lowered to $88 from $94 at Chardan
Chardan lowered the firm’s price target on Intellia Therapeutics (NTLA) to $88 from $94 and keeps a Buy rating on the shares after ...
Intellia slips after mid-stage data for CRISPR-based hereditary angioedema therapy
Intellia Therapeutics (NTLA) stock fell ~9% in reaction to Phase 2 trial data for a CRISPR-based gene editing therapy for ...
Why Is Gene Therapy-Focused Intellia Therapeutics Stock Trading Lower On Thursday?
Intellia Therapeutics' Phase 2 data shows NTLA-2002, a CRISPR gene therapy, reduced hereditary angioedema attack rates by up to 81%, with complete responses.
CRISPR-Cas9 gene editing trial results support further development as treatment for hereditary angioedema
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with ...
EurekAlert!14h
Phase Two results with CRISPR-Cas9 gene editing support further development as treatment for hereditary angioedema (HAE)
A single treatment with, a CRISPR-Cas9 based gene editing therapy, is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...